149 related articles for article (PubMed ID: 31124130)
1. Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.
Gutjahr A; Heck F; Emtenani S; Hammers AK; Hundt JE; Muck P; Siegel DL; Schmidt E; Stanley JR; Zillikens D; Hammers CM
Br J Dermatol; 2019 Sep; 181(3):593-594. PubMed ID: 31124130
[No Abstract] [Full Text] [Related]
2. The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies.
Kasprick A; Holtsche MM; Rose EL; Hussain S; Schmidt E; Petersen F; Panicker S; Ludwig RJ
J Invest Dermatol; 2018 Feb; 138(2):458-461. PubMed ID: 28899686
[No Abstract] [Full Text] [Related]
3. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
Menzinger S; Kaya G; Schmidt E; Fontao L; Laffitte E
Acta Derm Venereol; 2018 Feb; 98(2):284-286. PubMed ID: 29136264
[No Abstract] [Full Text] [Related]
4. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
[No Abstract] [Full Text] [Related]
5. Anti-desmogleins autoantibodies detected by ELISA and blotting in bullous pemphigoid: what do they mean?
Julio T; Vernal S; Turatti A; Roselino AM
Int J Dermatol; 2018 Jan; 57(1):124-127. PubMed ID: 29152717
[No Abstract] [Full Text] [Related]
6. Immune complex and complement-mediated leukocyte recruitment in bullous pemphigoid.
Gammon WR
Immunol Ser; 1989; 46():509-25. PubMed ID: 2488868
[No Abstract] [Full Text] [Related]
7. Autoantibody serum levels and intensity of pruritus in bullous pemphigoid.
Bardazzi F; Barisani A; Magnano M; Tengattini V; La Placa M; Patrizi A; Balestri R
Eur J Dermatol; 2016 Aug; 26(4):390-1. PubMed ID: 27210833
[No Abstract] [Full Text] [Related]
8. Serological investigation of bullous scabies and review of the published work.
Kokubu H; Takahashi T; Tateishi C; Tsuruta D; Hashimoto T; Tanaka T; Fujimoto N
J Dermatol; 2019 Sep; 46(9):e324-e325. PubMed ID: 30969443
[No Abstract] [Full Text] [Related]
9. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.
Fania L; Didona D; Pacifico V; Mariotti F; De Luca N; Abeni D; Mazzanti C; Di Zenzo G; Didona B
J Dermatol; 2018 Sep; 45(9):1135-1140. PubMed ID: 30007013
[TBL] [Abstract][Full Text] [Related]
10. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
[No Abstract] [Full Text] [Related]
11. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
[TBL] [Abstract][Full Text] [Related]
12. Sensitivities and utility of non-invasive serological tests in the diagnosis of bullous pemphigoid.
Yew YW; Tey HL
Int J Dermatol; 2016 Sep; 55(9):e510-1. PubMed ID: 27028937
[No Abstract] [Full Text] [Related]
13. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
Schauer F; Kern JS; Virtic O; Technau-Hafsi K; Meiss F; Thoma K; Athanasiou I; Sitaru C; Di Zenzo G; Izumi K; Nishie W; Shimizu H; Bruckner-Tuderman L; Kiritsi D
Br J Dermatol; 2019 Jan; 180(1):231-232. PubMed ID: 30188568
[No Abstract] [Full Text] [Related]
14. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid.
Delaumenie S; Assikar S; Prudhomme R; Matei I; Souyri N; Dalmay F; Bedane C
Eur J Dermatol; 2019 Apr; 29(2):217-218. PubMed ID: 30734720
[No Abstract] [Full Text] [Related]
16. Erythema Multiforme-Like Bullous Pemphigoid.
Imbernón-Moya A; Aguilar A; Burgos F; Gallego MÁ
Actas Dermosifiliogr; 2016 Oct; 107(8):689-91. PubMed ID: 27048923
[No Abstract] [Full Text] [Related]
17. A case of bullous pemphigoid with IgG antibodies against LAD-1, but not BP180 NC16a domain or BP230.
Miyashita K; Iioka H; Miyagawa F; Ishii N; Hashimoto T; Asada H
Eur J Dermatol; 2018 Apr; 28(2):248-250. PubMed ID: 29378676
[No Abstract] [Full Text] [Related]
18. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.
Salz M; Haeberle S; Hoffmann J; Enk AH; Hadaschik EN
J Dermatol Sci; 2017 Sep; 87(3):309-311. PubMed ID: 28823642
[No Abstract] [Full Text] [Related]
19. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
Ma L; Wang M; Wang X; Chen X; Zhu X
J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
[No Abstract] [Full Text] [Related]
20. Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.
Zheng M; Ujiie H; Iwata H; Muramatsu K; Yoshimoto N; Ito T; Ujiie I; Shimizu S; Sato-Matsumura KC; Shimizu H
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):595-600. PubMed ID: 30394605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
